Options for prandial glucose management in type 2 diabetes patients using basal insulin: Addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy

I. B. Hirsch, J. B. Buse, J. Leahy, J. B. Mcgill, A. Peters, H. W. Rodbard, R. R. Rubin, Jay S Skyler, C. A. Verderese, M. C. Riddle

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Integrating patient-centered diabetes care and algorithmic medicine poses particular challenges when optimized basal insulin fails to maintain glycaemic control in patients with type 2 diabetes. Multiple entwined physiological, psychosocial and systems barriers to insulin adherence are not easily studied and are not adequately considered in most treatment algorithms. Moreover, the limited number of alternatives to add-on prandial insulin therapy has hindered shared decision-making, a central feature of patient-centered care. This article considers how the addition of a glucagon-like peptide 1 (GLP-1) analogue to basal insulin may provide new opportunities at this stage of treatment, especially for patients concerned about weight gain and risk of hypoglycaemia. A flexible framework for patient-clinician discussions is presented to encourage development of decision-support tools applicable to both specialty and primary care practice.

Original languageEnglish
Pages (from-to)206-214
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Glucagon-Like Peptide 1
Type 2 Diabetes Mellitus
Meals
Insulin
Glucose
Patient-Centered Care
Therapeutics
Hypoglycemia
Weight Gain
Primary Health Care
Decision Making
Medicine

Keywords

  • GLP-1 analogue
  • Insulin analogues
  • Insulin intensive management

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Options for prandial glucose management in type 2 diabetes patients using basal insulin : Addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. / Hirsch, I. B.; Buse, J. B.; Leahy, J.; Mcgill, J. B.; Peters, A.; Rodbard, H. W.; Rubin, R. R.; Skyler, Jay S; Verderese, C. A.; Riddle, M. C.

In: Diabetes, Obesity and Metabolism, Vol. 16, No. 3, 01.03.2014, p. 206-214.

Research output: Contribution to journalArticle

Hirsch, I. B. ; Buse, J. B. ; Leahy, J. ; Mcgill, J. B. ; Peters, A. ; Rodbard, H. W. ; Rubin, R. R. ; Skyler, Jay S ; Verderese, C. A. ; Riddle, M. C. / Options for prandial glucose management in type 2 diabetes patients using basal insulin : Addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. In: Diabetes, Obesity and Metabolism. 2014 ; Vol. 16, No. 3. pp. 206-214.
@article{8fbc6efaca8d4ec59fe88eee7186bb9b,
title = "Options for prandial glucose management in type 2 diabetes patients using basal insulin: Addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy",
abstract = "Integrating patient-centered diabetes care and algorithmic medicine poses particular challenges when optimized basal insulin fails to maintain glycaemic control in patients with type 2 diabetes. Multiple entwined physiological, psychosocial and systems barriers to insulin adherence are not easily studied and are not adequately considered in most treatment algorithms. Moreover, the limited number of alternatives to add-on prandial insulin therapy has hindered shared decision-making, a central feature of patient-centered care. This article considers how the addition of a glucagon-like peptide 1 (GLP-1) analogue to basal insulin may provide new opportunities at this stage of treatment, especially for patients concerned about weight gain and risk of hypoglycaemia. A flexible framework for patient-clinician discussions is presented to encourage development of decision-support tools applicable to both specialty and primary care practice.",
keywords = "GLP-1 analogue, Insulin analogues, Insulin intensive management",
author = "Hirsch, {I. B.} and Buse, {J. B.} and J. Leahy and Mcgill, {J. B.} and A. Peters and Rodbard, {H. W.} and Rubin, {R. R.} and Skyler, {Jay S} and Verderese, {C. A.} and Riddle, {M. C.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1111/dom.12136",
language = "English",
volume = "16",
pages = "206--214",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Options for prandial glucose management in type 2 diabetes patients using basal insulin

T2 - Addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy

AU - Hirsch, I. B.

AU - Buse, J. B.

AU - Leahy, J.

AU - Mcgill, J. B.

AU - Peters, A.

AU - Rodbard, H. W.

AU - Rubin, R. R.

AU - Skyler, Jay S

AU - Verderese, C. A.

AU - Riddle, M. C.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Integrating patient-centered diabetes care and algorithmic medicine poses particular challenges when optimized basal insulin fails to maintain glycaemic control in patients with type 2 diabetes. Multiple entwined physiological, psychosocial and systems barriers to insulin adherence are not easily studied and are not adequately considered in most treatment algorithms. Moreover, the limited number of alternatives to add-on prandial insulin therapy has hindered shared decision-making, a central feature of patient-centered care. This article considers how the addition of a glucagon-like peptide 1 (GLP-1) analogue to basal insulin may provide new opportunities at this stage of treatment, especially for patients concerned about weight gain and risk of hypoglycaemia. A flexible framework for patient-clinician discussions is presented to encourage development of decision-support tools applicable to both specialty and primary care practice.

AB - Integrating patient-centered diabetes care and algorithmic medicine poses particular challenges when optimized basal insulin fails to maintain glycaemic control in patients with type 2 diabetes. Multiple entwined physiological, psychosocial and systems barriers to insulin adherence are not easily studied and are not adequately considered in most treatment algorithms. Moreover, the limited number of alternatives to add-on prandial insulin therapy has hindered shared decision-making, a central feature of patient-centered care. This article considers how the addition of a glucagon-like peptide 1 (GLP-1) analogue to basal insulin may provide new opportunities at this stage of treatment, especially for patients concerned about weight gain and risk of hypoglycaemia. A flexible framework for patient-clinician discussions is presented to encourage development of decision-support tools applicable to both specialty and primary care practice.

KW - GLP-1 analogue

KW - Insulin analogues

KW - Insulin intensive management

UR - http://www.scopus.com/inward/record.url?scp=84893476248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893476248&partnerID=8YFLogxK

U2 - 10.1111/dom.12136

DO - 10.1111/dom.12136

M3 - Article

C2 - 23711193

AN - SCOPUS:84893476248

VL - 16

SP - 206

EP - 214

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -